Aspira Women’s Health 

Aspira Women's Health, Inc. engages in the provision of bio-analytic and diagnostic services. Its product, OVA1, is a serum test for identifying women of having malignant ovarian tumor. Its bio-analytical solutions helps physicians diagnose, treat, and improve gynecologic health outcomes for women. The company was founded on December 9, 1993 and is headquartered in Austin, TX.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Aspira Women's Health (AWH) sees robust growth and innovation in Q1 2024

Aspira Women's Health (AWH) reported strong performance in Q1 2024, driven by significant growth in test volumes and improvements in financial metrics. The company's focus on innovation and collaboration underscores its commitment to advancing women's health diagnostics. While challenges in funding persist, AWH's strategic initiatives and market opportunities position it for continued growth and success in the future.

Aspira Women's Health achieves record test volumes amidst cost challenges

AWH reported strong performance in test volumes and revenue growth in Q2 2024.
While facing challenges with margins and costs, the company is actively addressing them.
Opportunities lie in product development, market expansion, and cost control measures.
Overall, AWH is strategically positioned for growth and innovation in the women's health sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CEO Nicole Sandford will step down for personal reasons and will remain as a consultant to ensure a seamless transition CEO Nicole Sandford will step down for personal reasons and will remain as a consultant to ensure a seamless transition

Aspira Women's Health Announces Appointment of Dr. Sandra Milligan as Interim CEO

The Company received the first $2 million from the ARPA-H Sprint for Women's Health Award The Company received the first $2 million from the ARPA-H Sprint for Women's Health Award

Aspira Women's Health Successfully Reaches the First Milestone of the ARPA-H $10 Million Award

Aspira (AWH) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to loss of $0.48 per share a year ago.

Aspira (AWH) Reports Q3 Loss, Lags Revenue Estimates

Aspira Women's Health Inc. (NASDAQ:AWH ) Q3 2024 Earnings Conference Call November 14, 2024 8:30 AM ET Company Participants Nicole Sandford - Chief Executive Officer & Director Sandy Milligan - President John Kallassy - Interim Chief Financial Officer Conference Call Participants Operator Good morning, ladies and gentlemen and welcome to Aspira Women's Health Incorporated Third Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.

Aspira Women's Health Inc. (AWH) Q3 2024 Earnings Call Transcript

Management to Announce Earnings Results and hold a call at 8:30 am ET Management to Announce Earnings Results and hold a call at 8:30 am ET

Aspira Women's Health to Announce Third Quarter Earnings Results and Host a Conference Call on Thursday, November 14, 2024

Event to feature presentations from Dr. Kevin Elias, Dr. Richard Gersh, Dr. Sandra Milligan, and Dr. Todd Pappas on the Company's development pipeline Event to feature presentations from Dr. Kevin Elias, Dr. Richard Gersh, Dr. Sandra Milligan, and Dr. Todd Pappas on the Company's development pipeline

Aspira Women's Health Issues Letter to Shareholders and Announces Virtual Research & Development Day on October 29, 2024

Aspira aims to develop a multi-marker miRNA blood test to aid in the detection of endometriosis Aspira aims to develop a multi-marker miRNA blood test to aid in the detection of endometriosis

Aspira Women's Health Selected to Receive $10 Million Award from ARPA-H's Sprint for Women's Health

New York State Department of Health (NYSDOH) Clinical Laboratory Evaluation (CLEP) approval allows for OvaWatch® to be marketed in New York State New York State Department of Health (NYSDOH) Clinical Laboratory Evaluation (CLEP) approval allows for OvaWatch® to be marketed in New York State

Aspira Women's Health Receives Approval from New York State Department of Health for OvaWatch®

Annex Insurance (AWH, Financial) stock recently experienced a sharp decline, dropping 7.47% to $0.761 per share. The trading volume stood at 16,266 shares, with a turnover rate of 0.10% and a price fluctuation of 2.62%.

AWH Stock Plummets as Financial Data Reflects Losses

Aspira Womens Health (AWH, Financial) experienced a significant stock price drop of 7.80%, reaching $0.775 per share. The trading volume stood at 14,064 shares with a turnover rate of 0.09% and a volatility of 7.47%.

Aspira Womens Health (AWH) Shares Plunge Amid Financial Challenges

AUSTIN, Texas, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that Nicole Sandford, CEO of Aspira Women's Health will present at the H.C. Wainwright 26th Annual Global Investment Conference being held September 9-11, 2024 at the Lotte New York Palace Hotel in New York, NY.

Aspira Women's Health to Present at the H.C. Wainwright 26th Annual Global Investment Conference

AWH's partnership with Dorsata is set to help with the adnexal masses diagnosis and treatment.

Dorsata's Alliance on Adnexal Masses to Support Aspira Stock

Aspira Women's Health Inc. (NASDAQ:AWH ) Q2 2024 Earnings Conference Call August 12, 2024 4:30 PM ET Company Participants Nicole Sandford - CEO and Director Sandy Milligan - President Conference Call Participants Ross Osborn - Cantor Fitzgerald Do Kim - Water Tower Research Operator Good morning, ladies and gentlemen. And welcome to Aspira Women's Health, Incorporated Second Quarter 2024 Earnings Conference Call.

Aspira Women's Health Inc. (AWH) Q2 2024 Earnings Call Transcript

Aspira (AWH) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to loss of $0.28 per share a year ago.

Aspira (AWH) Reports Q2 Loss, Misses Revenue Estimates

Q2 2024 OvaSuite S M revenue of $2.4 million and volume of 6,471 units

Aspira Women's Health Reports Second Quarter 2024 Financial Results

AUSTIN, Texas, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced a poster presentation at the 27th Annual National Association of Nurse Practitioner's in Women's Health (NPWH) Woman's Healthcare Conference being held on September 25-28, 2024, in Chicago, IL. Presentation details are as follows:

Aspira Women's Health's Announces a Poster Presentation at the 27th Annual National Association of Nurse Practitioners in Women's Health (NPWH) Women's Healthcare Conference

AUSTIN, Texas, July 09, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that it has closed its previously announced private placement for the issuance and sale of shares of the Company's common stock and accompanying warrants to purchase an equal number of shares for gross proceeds of approximately $1.9 million. Aspira has the potential to receive additional gross proceeds of up to $2.8 million, before deducting offering expenses, upon the full cash exercise of warrants issued in the private placement.

Aspira Women's Health Announces Closing of $1.9 Million Private Placement Equity Financing

AUSTIN, Texas, July 01, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced it has entered into a securities purchase agreement dated June 30, 2024 with certain existing accredited shareholders and Company insiders to issue and sell an aggregate of 1,264,739 shares of its common stock (“Common Stock”) and warrants to purchase an equal number of shares of Common Stock (“Warrants”) at a combined offering price of $1.53 per share and warrant through a private placement financing (the “Offering”). Aspira anticipates the gross proceeds from the Offering will be approximately $1.935 million, before deducting offering expenses. The warrants will be exercisable for three years after date of issuance and have an exercise price of $2.25 per share. The Offering is expected to close by July 8, 2024 subject to customary closing conditions. Net proceeds from the Offering will support Aspira's ongoing commercial activities as well as general corporate purposes and working capital.

Aspira Women's Health Announces $1.935 Million Private Placement Equity Financing

Monthly OvaSuiteSM  product volume grew by more than 26% in May compared to January Reimbursement momentum continued with expanded Anthem and Medicaid coverage for OvaSuite Cash used in operations guidance for 2024 expected to be lowered AUSTIN, Texas, June 13, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today provided interim commercial and operational updates for the second quarter of 2024. Product volume continued its sustained monthly gains, growing by more than 26% in May 2024 compared to January 2024.

Aspira Women's Health Provides Commercial, Reimbursement and Cash Guidance Updates

AUSTIN, Texas, May 16, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that management will present a corporate overview at the Alliance Global Partner's Healthcare Showcase taking place virtually on Tuesday, May 21, 2024.

Aspira Women's Health to Present at the A.G.P. Healthcare Showcase on May 21

Aspira Women's Health Inc. (NASDAQ:AWH ) Q1 2024 Results Conference Call May 15, 2024 8:30 AM ET Company Participants Nicole Sandford - CEO Sandy Milligan - President Torsten Hombeck - CFO Conference Call Participants Ross Osborn - Cantor Fitzgerald Maggie Boeye - William Blair Do Kim - Water Tower Research Operator Good morning, ladies and gentlemen, and welcome to Aspira Women's Health, Incorporated. First Quarter 2024 Earnings Conference Call.

Aspira Women's Health Inc. (AWH) Q1 2024 Earnings Call Transcript

Aspira (AWH) came out with a quarterly loss of $0.39 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to loss of $10.94 per share a year ago.

Aspira (AWH) Reports Q1 Loss, Tops Revenue Estimates

Q1 2024 OvaSuite S M revenue of $2.2 million and volume of 5,829 units

Aspira Women's Health Reports First Quarter 2024 Financial Results

AUSTIN, Texas, May 08, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that the Company will report its financial results for the three months ended March 31, 2024, on Wednesday, May 15, 2024. Management will also host a conference call at 8:30 a.m. Eastern Time to discuss financial results and provide a corporate update. Details for the call are as follows:

News for Aspira Women’s Health Stock (AWH)